Technical Analysis for SRPT - Sarepta Therapeutics, Inc.

Grade Last Price % Change Price Change
B 90.57 0.03% 0.03
SRPT closed up 0.03 percent on Friday, September 24, 2021, on 1.28 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical SRPT trend table...

Date Alert Name Type % Chg
Shooting Star Candlestick Bearish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Crossed Above 200 DMA Bullish 0.03%
Pocket Pivot Bullish Swing Setup 0.03%
Upper Bollinger Band Walk Strength 0.03%
Multiple of Ten Bullish Other 0.03%
Older End-of-Day Signals for SRPT ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Pocket Pivot 1 day ago
Possible NR7 1 day ago
Up 1% 1 day ago
2x Volume Pace 1 day ago
1.5x Volume Pace 1 day ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Sarepta Therapeutics, Inc. Description

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is eteplirsen, an antisense PMO-based therapeutic, which is in Phase IIb clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Clinical Development Infectious Diseases Rare Diseases Clinical Research Influenza Dystrophy Muscular Dystrophy Duchenne Muscular Dystrophy Duchenne Therapeutic Gene Modulation Antisense RNA Sarepta Therapeutics

Is SRPT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 181.83
52 Week Low 65.3
Average Volume 746,949
200-Day Moving Average 88.55
50-Day Moving Average 76.91
20-Day Moving Average 82.49
10-Day Moving Average 86.01
Average True Range 2.89
ADX 36.16
+DI 34.44
-DI 7.57
Chandelier Exit (Long, 3 ATRs) 83.13
Chandelier Exit (Short, 3 ATRs) 84.01
Upper Bollinger Bands 91.04
Lower Bollinger Band 73.95
Percent B (%b) 0.97
BandWidth 20.72
MACD Line 3.39
MACD Signal Line 2.61
MACD Histogram 0.7826
Fundamentals Value
Market Cap 7.15 Billion
Num Shares 78.9 Million
EPS -8.14
Price-to-Earnings (P/E) Ratio -11.13
Price-to-Sales 23.81
Price-to-Book 13.56
PEG Ratio 159.25
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 93.09
Resistance 3 (R3) 93.21 92.50 92.67
Resistance 2 (R2) 92.50 91.85 92.44 92.53
Resistance 1 (R1) 91.53 91.46 92.02 91.41 92.39
Pivot Point 90.82 90.82 91.06 90.76 90.82
Support 1 (S1) 89.85 90.17 90.34 89.73 88.75
Support 2 (S2) 89.14 89.78 89.08 88.61
Support 3 (S3) 88.17 89.14 88.47
Support 4 (S4) 88.05